AngioDynamics Awarded Premier’s Nationally Outsourced Implantable Infusion Port Agreement
September 09 2019 - 8:00AM
Business Wire
AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of
innovative, minimally invasive medical devices for vascular access,
peripheral vascular disease, and oncology, today announced that the
Company has been awarded a dual-source group purchasing agreement
by Premier, Inc. to supply implantable infusion ports. The
three-year agreement becomes effective on November 1, 2019 and
allows Premier Members to take advantage of pre-negotiated pricing
and terms for AngioDynamics’ Smart Port®, BioFlo®, Vortex®, and
Xcela® port technologies.
In addition to the new dual-source agreement, AngioDynamics was
also awarded sole-source agreements for Premier’s SURPASS and
ASCEND members.
“We are excited to provide Premier members with our
market-leading implantable infusion ports along with the
world-class support of our committed sales and marketing
organization,” said Chad Campbell, AngioDynamics senior vice
president and general manager for Vascular Access. “Premier’s
extensive member network provides AngioDynamics with access to a
large, diverse market for its innovative medical device technology.
We hope to leverage this partnership to drive further value for our
new and existing health care partners to achieve the shared goal of
improving patient outcomes.”
Premier is a leading healthcare improvement company, uniting an
alliance of approximately 4,000 U.S. hospitals and 165,000 other
providers to transform healthcare. With integrated data and
analytics, collaboratives, supply chain solutions, and advisory and
other services, Premier enables better care and outcomes at a lower
cost.
About AngioDynamics, Inc.
AngioDynamics, Inc. is a leading provider of innovative,
minimally invasive medical devices used by professional healthcare
providers for vascular access, peripheral vascular disease, and
oncology. AngioDynamics’ diverse product lines include
market-leading ablation systems vascular access products,
angiographic products and accessories, drainage products,
thrombolytic products and venous products. For more information,
visit www.angiodynamics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190909005265/en/
Investor Relations Contact: AngioDynamics, Inc. Michael
Greiner 518-795-1821 mgreiner@angiodynamics.com
Media Contact: AngioDynamics, Inc. Saleem Cheeks
518-795-1174 scheeks@angiodynamics.com
AngioDynamics (NASDAQ:ANGO)
Historical Stock Chart
From Mar 2024 to Apr 2024
AngioDynamics (NASDAQ:ANGO)
Historical Stock Chart
From Apr 2023 to Apr 2024